Matt Cooper

Dr. Cooper brings extensive experience in life science platforms, clinical diagnostics and therapeutics for inflammatory, autoimmune and infectious diseases. He has founded or co-founded six companies including Sitala and Inflazome both of which are in the Forbion portfolio. The latter was acquired in September 2020 by Roche for $450m plus further substantial milestone payments. He was also the founder of the Center for Superbug Solutions, Community for Open Access Antibiotic Discovery & Center for Drug Discovery and Design at the University of Queensland, where he was a NHMRC Australia Fellow, following research at Cambridge University. Dr. Cooper has more than 350 academic publications and over 200 patents and is a Fellow of the Royal Society of Chemistry.